M&A Deal Summary

Viatris Acquires Renaissance Acquisition - Specialty and Generics Business

On May 13, 2016, Viatris acquired life science company Renaissance Acquisition - Specialty and Generics Business from Renaissance Lakewood for 1.0B USD

Acquisition Highlights
  • This is Viatris’ 7th transaction in the Life Science sector.
  • This is Viatris’ 5th largest (disclosed) transaction.
  • This is Viatris’ 1st transaction in Canada.
  • This is Viatris’ 1st transaction in Quebec.

M&A Deal Summary
Date 2016-05-13
Target Renaissance Acquisition - Specialty and Generics Business
Sector Life Science
Buyer(s) Viatris
Sellers(s) Renaissance Lakewood
Deal Type Divestiture
Deal Value 1.0B USD

Target

Renaissance Acquisition - Specialty and Generics Business

Quebec, Canada
Renaissance Acquisition - Specialty and Generics Business comprises portfolio of specialty brands and generic products in the dermatology space, as well as a deep pipeline of complex topical generics and brands in active development. The Business has two high-quality manufacturing sites with capabilities and capacity in creams, ointments, aerosols/foams, gels, suspensions, liquids and suppositories that are complementary to Mylan's existing capabilities.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Viatris

Canonsburg, Pennsylvania, United States
Category Company
Founded 1961
Sector Life Science
Employees33,000
Revenue 15.4B USD (2023)
DESCRIPTION

Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.

DEAL STATS #
Overall 10 of 13
Sector (Life Science) 7 of 10
Type (Divestiture) 4 of 6
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2016) 2 of 2
Size (of disclosed) 5 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-10 Meda

Solna, Sweden

Meda is an operator of an international specialty pharma company that is fully represented in Europe and the US through its own sales organizations in more than 50 countries. Meda’s products are sold in about 120 countries, and where it lacks a sales organization, it markets and sells its products via agents and other pharmaceutical companies. Meda has a diversified geographic footprint with approximately 62 percent of Meda's sales generated in Western Europe (the largest countries being Italy, Germany, France, and Sweden), 19 percent in Emerging Markets (driven by China, Russia, the Middle East, and Thailand) and 17 percent in the U.S. Meda has a network of seven manufacturing facilities in Europe, the U.S. and India. Meda is based in Solna, Sweden.

Buy $9.9B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-09 Cold-EEZE

Doylestown, Pennsylvania, United States

Cold-EEZE is a cold remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold.

Buy -

Seller(S) 1

SELLER

Renaissance Lakewood

Lakewood, New Jersey, United States
Category Company
Founded 2010
Sector Life Science
DESCRIPTION

Renaissance Lakewood is a pharmaceutical company that offers contract development and manufacturing, and commercialization of branded and generic prescription products. Renaissance Lakewood was founded in 2010 and is based in Lakewood, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-07-05 DPT Laboratories

San Antonio, Texas, United States

DPT Laboratories Ltd. is a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms.

Buy -
Mergr

Product

Company

Legal